Introduction
============

The heart is the first organ to develop during embryogenesis. In the developing mouse heart, between embryonic day (E) 11.5 and E14.5, cardiac cells undergo differentiation, migration, and proliferation driving cardiac tissue morphogenic events including chamber septation, heart valve formation, myocardial compaction, and coronary vessel formation, all essential for proper heart development.^[@b1]--[@b4]^ These processes are directed by cardiac transcriptional programs and endocardial‐myocardial molecular signalings.^[@b5]--[@b8]^ Both genetic and epigenetic mechanisms have been shown to control the expression of cardiac genes in a spatiotemporal manner during heart development.^[@b9]--[@b13]^

Epigenetic modifications, including DNA methylation and histone modification, regulate gene expression by changing the local chromatin structure, thus altering the interaction of chromatin and DNA‐binding proteins, such as the binding of transcription activators and repressors to gene promoters and enhancers.^[@b14]--[@b16]^ Different from genetic variation, epigenetic modifications regulate gene expression without altering the nucleotide sequence. In the case of DNA methylation, a methyl group is added to the carbon 5 of cytosine located at a CpG dinucleotide. It has been shown that DNA methylation is essential for gene regulation during development, especially that of tissue‐specific genes, and help to maintain cell and tissue identity.^[@b17]--[@b19]^ Notably, with the exception of imprinted genes, the mammalian genome is stripped of its epigenetic modifications in early embryogenesis and the epigenome is then re‐established throughout embryonic development.^[@b20]--[@b22]^

Globally, the patterns of DNA methylation acquired during embryogenesis remain stable throughout development and adulthood.^[@b19]^ However, changes in DNA methylation at individual loci do occur and can alter expression of genes with important biological functions in development and disease.^[@b23]--[@b24]^ DNA methylation change also occurs in response to developmental perturbations, such as hypoxia. Altered levels of 5‐methylcytosine, either genome wide or at specific gene loci, have been related to increased disease susceptibility, and dysregulation of DNA methylation has been linked to cardiovascular disease, type II diabetes, and cancer.^[@b24]--[@b26]^

Most studies on DNA methylation have focused on gametogenesis, development, disease, and stem cell function by demonstrating how it regulates gene expression and cell differentiation.^[@b23],[@b27]--[@b30]^ Few studies, however, have been devoted to understand the roles of DNA methylation in heart development. Determining the landscape of DNA methylation in this process is an essential step for understanding how DNA methylation regulates the cardiac genes essential for heart development.

Towards this end, we have applied a genome‐wide approach in this study to profile developmental changes in DNA methylation in mouse embryonic hearts between E11.5 and E14.5. The morphogenic events occurring during this developmental window are less well studied than early morphogenic events such as the differentiation of cardiac cells. The results show that while the DNA methylome is stable during development, differential methylation occurs at a small subset of genes highly associated with cardiac tissue differentiation and heart development and reveal a regulatory relationship between differential DNA methylation and cardiac essential gene expression. Thus, these results provide new information on the regulation of cardiac gene expression and heart development by DNA methylation.

Methods
=======

Animals (Mice)
--------------

ICR wild‐type mice were bred in‐house for timed pregnancies. Noontime on the day of first observing vaginal plugs was designated as embryonic day (E) 0.5. For *Dnmt3b* knockout studies, endocardial specific Cre mice (*Nfatc1*^*Cre*^)^[@b9]^ were crossed with floxed *Dnmt3b* (DNA methyltransferase 3b) mice (obtained from The Jackson Laboratory) to delete *Dnmt3b* in heart valves. Conditional knockout (CKO) and control embryos were identified via PCR genotyping. All mouse experiments were performed according to the protocol approved by the Institutional Animal Care and Use Committee of Albert Einstein College of Medicine.

Methyl Sensitive Tiny Fragment Enrichment/Massively Parallel Sequencing (MSFE/MPS)
----------------------------------------------------------------------------------

Embryonic hearts from E11.5 or E14.5 were isolated from pregnant mice and non‐cardiac tissues were removed. Genomic DNA was extracted from 4 groups of pooled hearts as described previously.^[@b31]^ A total of 5 μg of extracted DNA from each group was used for a modified HELP‐tagging assay.^[@b32]^ We modified the original assay by replacing HpaII with HpyCH4IV, the restriction enzyme recognizing 5′‐ACGT‐3′ sites and sensitive to methylation at the CG. After HpyCH4IV digestion, the sequencing libraries were generated using the Ligation Mediated PCR Assay (LMPA).^[@b33]^ The generated libraries were submitted to the Epigenomics Shared Facility at the Albert Einstein College of Medicine for massively parallel sequencing. Sequencing was performed on individual libraries prepared from 2 biological replicates for each group. The quality of the sequencing results was determined by the parameters of length and peak value of sequence reads. The raw and processed data have been submitted to GEO (accession number: GSE55141).

Luminometric Methylation Assay to Validate the Global DNA Methylation
---------------------------------------------------------------------

Global DNA methylation for each biological replicate, at both E11.5 and E14.5, was confirmed using the Luminometric Methylation Assay (LUMA) as described previously.^[@b34]--[@b35]^ Genomic DNA was digested for 4 hours with HpyCH4IV and EcoRI, purified and pyrosequenced at the Einstein Genomics Core.

MassArray
---------

Loci with differential methylation, ranging from 0% to 100% determined by the massively parallel sequencing, were randomly selected and validated using Sequenom\'s MassArray.^[@b36]^ Primers were designed using MethPrimer and T7 tags were added as per the Sequenom MassArray protocol ([Table 1](#tbl01){ref-type="table"}). Genomic DNA (0.6 μg) from 3 replicates (for technical validation) and 2 replicates (for experimental validation) was bisulfite converted using the Zymo Research EZ DNA Methylation Kit prior to amplification using the MassArray Primers. Amplified bisulfite‐converted genomic DNA was then subjected to MassArray on a Sequenom machine.

###### 

Loci and Primers (With T7 Tags, Lower Cases) for Initial Technical Validation by MassArray

  --------------------------------------------------------------------------------------------
  ACGT Location     Forward Primer With T7 Balance (Top) Reverse Primer With T7 Tag (Bottom)
  ----------------- --------------------------------------------------------------------------
  Chr4 145913471    aggaagagagAGTTTTTATGTTTTTTGTAAGGTTATTTGA\
                    cagtaatacgactcactatagggagaaggctCCAAACTCCTAATCCCAATCTAAC

  Chr7 147043670    aggaagagagTTGGGGGTTTTTAATTAAGATAGTTT\
                    cagtaatacgactcactatagggagaaggctTTCCCTCTAATATATCCCATTTTACC

  Chr12 62103733    aggaagagagAGTATTAGGGTTAAGTATTGAATAAATTTA\
                    cagtaatacgactcactatagggagaaggctAATCAAAATAAAAAATCAAAAAAAA

  Chr11 4347732     aggaagagagTTTAGGTATATATTATTATATTTGATTTTT\
                    cagtaatacgactcactatagggagaaggctAATTACCACAAAACCTAACAC

  Chr2 38354047     aggaagagagAGAGTGGTATTTGTGTTAGAGAGGA\
                    cagtaatacgactcactatagggagaaggctTTCCAAAAAAAACCAAAAAAAA

  Chr6 64724205     aggaagagagTGTTTTTGTAATTTAGATAAGATTATTTTA\
                    cagtaatacgactcactatagggagaaggctAATCACATATCACTAACCAAACAATATC

  Chr2 165155478    aggaagagagGGGTGATAGGAAGTTGTAGAGATTAGA\
                    cagtaatacgactcactatagggagaaggctAAAAAAACACTACCCAAACTTAAATAACA

  Chr11 3036940     aggaagagagGGGTATTTGTTTAAGATATTTTTGATTTAT\
                    cagtaatacgactcactatagggagaaggctACAATAACCAAATAAAAAACACACCA

  Chr12 101338922   aggaagagagTGGTGTTTTAGTTGTTAAAATGTTATAGG\
                    cagtaatacgactcactatagggagaaggctCAAAAATATTCCCCAAATATCAAAA

  Chr18 55862932    aggaagagagTAGAAAAATAGGGAGAATGTGATATT\
                    cagtaatacgactcactatagggagaaggctATATCTAACTTCCCTACACCCACTAAAA

  Chr1 25839243     aggaagagagTTTTAGGATTGAATAAAATTTTAAGA\
                    cagtaatacgactcactatagggagaaggctATTTAATTTACTCATTCTCTCTATATAC
  --------------------------------------------------------------------------------------------

Individual sites representing 0%, 25%, 50%, 75% or 100% methylation, that were consistent between the 2 assayed samples, were chosen for validation by Sequenom\'s MassArray to generate a standard by which to make calls on methylation levels. Primers were designed using MethPrimer and T7 tags were added as per the Sequenom guide.

Bioinformatic Analysis to Profile Genome‐Wide DNA Methylation
-------------------------------------------------------------

The sequencing reads were aligned to the mouse genome (mm9) and the number of mapped reads with their 5′ ends starting at each ACGT site was recorded using the automated data analysis pipeline created by the Epigenomics Center and the Computational and Statistical Epigenomics Group at Albert Einstein College of Medicine.^[@b32],[@b37]^ The read counts at individual ACGT sites from E11.5 and E14.5 were compared and sites with significantly different counts were determined by EdgeR, a Bioconductor package designed for analysis of count based genome‐wide sequencing data.^[@b38]^ The resultant sites were associated with genes if they were located to promoters, gene bodies, or within 50 kb of genes.

Gene Expression Analysis
------------------------

Custom TaqMan Array 96‐Well Fast Plates (Applied Biosystems) were designed for candidate genes prioritized based on degree of differential methylation, function, and presence of multiple‐associated differentially methylated ACGT sites. RNA was extracted from pooled embryonic hearts from E11.5 or E14.5 (n=3 for each stage) and atrioventricular junctions isolated from 3 wild‐type or 3 CKO embryos at E11.5 and E14.5 using Trizol Reagent (Invitrogen) and reverse transcribed using the SuperScript II reverse transcription kit (Invitrogen). ΔCt values were calculated, normalizing to an endogenous control, and fold change was calculated using the 2^−ΔΔCt^ method.^[@b39]^

RNA In Situ Hybridization
-------------------------

RNA in situ hybridization for *Has2* expression in E11.5 or E14.5 hearts was carried out as described previously.^[@b5]^

Immunohistochemistry
--------------------

Immunohistochemistry (IHC) was carried out to determine expression of *Dnmt3b* in the developing heart using mouse monoclonal Dnmt3b antibody (Abcam 52A1018) (1:250), according to the Vector Labs mouse‐on‐mouse (M.O.M.) basic kit.

Statistical Analysis
--------------------

Pearson correlation was used to evaluate the overall similarity of MSFE/MPS tag counts between E11.5 and E14.5 samples. A linear regression was used to fit the relationship between tag counts and DNA methylation levels at 14 selected ACGT sites. Differentially methylated (DM) sites were identified by the program EdgeR,^[@b38]^ with \<5% FDR. A two‐sided *t* test was used to evaluate the difference of tag counts at ACGT sites located to different genomic contents, while hypergeometric test was used to evaluate the enrichment of DM sites in promoters and gene bodies. The statistical analysis of differential gene expression was performed using Microsoft Excel and the data were presented as mean±standard error (SE). Student *t* test was used for comparison between groups and *P* values \<0.05 were considered as significant, Bonferonni\'s correction was applied to account for multiple testing in gene expression analysis. For the expression analysis of 350 genes, Mann--Whitney test was also performed (data not shown). While the significance observed for the top 15 up‐ and down‐regulated genes in Figure [5](#fig05){ref-type="fig"}B remained, a few other differentially expressed genes included in Figure [5](#fig05){ref-type="fig"}A would lose statistical support.

Results
=======

Global DNA Methylation is Stable in the Developing Heart
--------------------------------------------------------

To study the importance of DNA methylation in heart development, we carried out a genome‐wide cytosine methylation analysis of E11.5 and E14.5 mouse embryonic hearts using MSFE/MPS with HpyCH4IV, a methylation‐sensitive restriction enzyme recognizing ACGT. A total of 75 278 236 and 28 496 681 sequencing reads were obtained from the 2 E11.5 replicates that were mapped to 1 522 872 and 1 447 993 ACGT sites, respectively, while 89 562 687 and 65 198 805 reads were generated from the 2 E14.5 replicates that were mapped to 1 442 766 and 1 490 463 sites, respectively. At both stages, the reads from the 2 replicates covered \>83% of the total 1 756 340 ACGT sites in the mouse genome. The Pearson\'s correlation coefficients were 0.894 and 0.896 between the 2 replicates for E11.5 and E14.5, respectively (data not shown); indicating that the quality of the data was high. The majority of ACGT sites had highly similar and correlated tag counts between E11.5 and E14.5 ([Figure 1](#fig01){ref-type="fig"}A), suggesting at the global level no significant methylation changes occurred between the 2 developmental stages. This finding of genome‐wide stable DNA methylation in the developing hearts was supported by the LUMA data ([Figure 1](#fig01){ref-type="fig"}B).

![Limited DNA methylation changes between E11.5 and E14.5 hearts. A, The tag counts for all ACGT sites in E11.5 (*x*‐axis) and E14.5 (*y*‐axis) are highly correlated. The depth of the color represents the density of points in a plotting area (n=2). B, Confirmation of stable global methylation by Luminometric Methylation Assay (LUMA) (n=2). Error bars represent standard error.](jah3-3-e000976-g1){#fig01}

Differential DNA Methylation Occurs Locally in the Developing Heart
-------------------------------------------------------------------

We then catalogued the ACGT sites into genic sites (−50 kb of transcription start sites \[TSS\] to +0.5 kb of transcription end sites \[TES\] and intergenic sites) ([Figure 2](#fig02){ref-type="fig"}A), with the former further separated into 3 types: promoter proximal sites (−5 kb to +0.5 kb of TSS), gene body sites (+0.5 kb of TSS to TES), and promoter distal or enhancer sites ([Figure 2](#fig02){ref-type="fig"}B, top panel), and also determined the distribution of ACGT tag counts across the genome by intersecting the genome‐wide ACGT methylation profiles with several genomic features, including CpG islands, CTCF‐binding sites, RefSeq genes, repetitive elements, and regulatory elements ([Figure 2](#fig02){ref-type="fig"}B, bottom panel). The gene annotation, CpG islands, and repeats were downloaded from the UCSC browser. Additionally, lists of regulatory elements for embryonic hearts were obtained from previous studies, including 3596 P300 binding sites identified for E11.5 hearts, 69 073 P300‐marked enhancers, 14 874 CTCF sites, and 45 981 regions with the H3K27ac modification (a histone mark for active enhancer) for E14.5.^[@b40]--[@b42]^

![Distribution of DNA methylation across the mouse genome and various types of genomic elements in the developing heart. A, Cartoon depicting the genic regions (enhancer, promoter and genebody). B, Violin plot (a combination of a box plot and a kernel density plot) showing the distributions of tag counts for all ACGT (top) or differential methylated (bottom) sites in different genomic regions. As number of tag counts is inversely correlated to level of CG methylation, these plots indicate that gene promoters and regulatory regions exhibit significantly lower levels of DNA methylation than genomic background, and repetitive sequences are highly methylated. Plots in orange and yellow are for data from E11.5 and E14.5, respectively. TES indicates transcription end sites; TSS, transcription start sites.](jah3-3-e000976-g2){#fig02}

The results showed that gene promoters and regulatory regions, represented by either CpG islands or enhancers (defined by P300 occupancy in E11.5 or H3K27ac enrichment in E14.5) had significantly lower levels of DNA methylation than genomic background, as ACGT sites within these regions had increased numbers of tag counts (*P*\<2.2e‐16, t test). Similarly, CTCF‐binding sites generally have low levels of methylation. This is consistent with previous reports that CTCF is associated with hypomethylated regions.^[@b43]^ In contrast, repetitive regions showed significantly higher levels of DNA methylation, as ACGT sites in these regions had decreased numbers of tag counts (*P*\<2.2e‐16, *t* test). Unexpectedly, the E14.5 cardiac enhancers exhibited higher DNA methylation than the elements marked by either P300 or H3K27ac at E14.5 ([Figure 2](#fig02){ref-type="fig"}B). This is probably due to the fact that those enhancers were identified based largely on H3K4me1 modifications, which is enriched in both active and poised enhancers.^[@b44]--[@b45]^

Next, we chose up to 14 ACGT sites with a range of different tag counts, representing 0%, 25%, 50%, 75%, or 100% methylation by massively parallel sequencing, and determined their levels of methylation by MassArray. The results indicated that tag count was inversely correlated with the percentage of cytosine methylation ([Figure 3](#fig03){ref-type="fig"}A), thereby confirming the precision of the MSFE/MPS in quantifying methylation level, ie, tag counts measured accurately both the global and regional DNA methylation. We then set out to investigate how much methylation changed in the developing hearts between E11.5 and E14.5. After normalization by sequencing depths, ACGT sites with at least 1 sequencing tag in any of the 4 samples were evaluated for differential methylation using 2 complementary approaches. We used EdgeR, which modeled the tag counts by a negative binomial distribution, to determine ACGT sites that showed differential methylation. The result indicated that the majority of the ACGT sites were not differentially methylated in the developing hearts between the 2 stages, as \<1% of sites were found to have different tags (nominal *P* value \<0.05) ([Figure 3](#fig03){ref-type="fig"}B). Among the small fraction (2901) of the ≈1.64 million analyzed ACGT sites that were differentially methylated, 1946 (67.1%) and 955 (32.9%) sites exhibited increased and decreased methylation in the late stage hearts, respectively (FDR\<0.05) ([Figure 3](#fig03){ref-type="fig"}C).^[@b38]^ Of note, for the majority of these sites, the degree of difference was \<50%, with no sites switching from a fully methylated to an unmethylated state.

![Analysis of the level of DNA methylation and differential methylation in the developing mouse heart. A, Methyl sensitive tiny fragment enrichment/massively parallel sequencing (MSFE/MPS) accurately detects levels of methylation as confirmed by Sequenom\'s MassArray of analyzed sites representing 0%, 25%, 50%, 75%, and 100% methylation determined by MSFE/MPS. B, Distribution of all ACGT sites with different numbers of tag counts from MSFE/MPS analysis. C, Violin plots showing the difference in tag counts for the 2901 ACGT sites that were significantly differentially methylated between E11.5 and E14.5. D, The distribution of all and differentially methylated (DM) ACGT sites in relation to gene annotation.](jah3-3-e000976-g3){#fig03}

We also compared the percentage of differentially methylated ACGT sites at various genic and intergenic regions with the percentage of the total analyzed ACGT sites located within the same defined regions. We found that the differentially methylated sites were significantly enriched in gene bodies (*P*\<2.2e‐16, hypergeometric test), as 51.6% of the differentially methylated sites versus 42.2% of all assayed sites were located to gene bodies ([Figure 3](#fig03){ref-type="fig"}D). On the contrary, differentially methylated ACGT sites were under‐represented in promoter (4.6%) and enhancer sites (13.9%), while 6.4% and 16.7% of all ACGT sites were in promoter‐proximal and enhancer regions, respectively. In total, 2032 (70%) of the 2901 sites were associated with genes, with 65.1% of them showing increased methylation at E14.5.

Differential DNA Methylation in the Developing Heart Links to Heart Development
-------------------------------------------------------------------------------

To investigate the functional importance of the small set of genes exhibiting differential methylation, we used the software GREAT to characterize the 2901 differentially methylated sites for their potential regulatory roles. Of the only 7 significantly associated gene ontology (GO) terms for biological processes returned by GREAT, 4 of them were related to heart development and cardiac tissue growth ([Figure 4](#fig04){ref-type="fig"}), indicating a significant enrichment of cardiac essential genes that have differential DNA methylation during heart development. These genes include *Erbb4*,*Gata6*,*Foxp1*,*Fgf2*,*Fgf9*,*Has2*,*Invs*,*Mef2c*,*Robo2*, and *Wnt2*. For example, *Foxp1* is important in cardiomyocyte proliferation,^[@b42],[@b46]^ while signaling from *Gata6* to *Wnt2* plays an important role in early cardiogenesis and inflow tract development,^[@b47]--[@b48]^ *Mef2c* plays an essential role in heart development as a regulator of cardiac myogenesis within the right ventricle,^[@b49]--[@b50]^ and *Has2* plays a role in heart valve development.^[@b6],[@b51]^ GREAT also reported that the affected genes were highly expressed in the cardiovascular system (*P*=5.3e‐5) and they were implicated in vascular disease (*P*=1.4e‐4) based on an analysis of Disease Ontology.^[@b52]^

![Gene ontology (GO) terms for the genes with differential DNA methylation during heart development. The software GREAT was used to characterize the 2901 differentially methylated sites for function. Four of the only 7 GO terms returned are involved in heart development and cardiac tissue growth.](jah3-3-e000976-g4){#fig04}

Differential DNA Methylation Corresponds to Changes in Gene Expression in the Developing Heart
----------------------------------------------------------------------------------------------

To directly test how the observed differential DNA methylation is related to gene expression changes in the developing heart, we picked 350 genes from the 1697 genes linked to the 2901 differentially methylated sites and performed qPCR to determine their expression levels in E11.5 and E14.5 hearts. These genes were chosen because they contained ACGT sites with a ≥50% change in methylation between the 2 stages, their known function (such as roles in embryonic development preferentially heart development), and/or presence of multiple differentially methylated sites. Change in mRNA level was calculated using the 2^−ΔΔCt^ method and genes were ranked based on fold change.^[@b39]^ Of the 350 genes assayed in the gene expression analysis, 181 (51.7%) genes, including *Erbb4*,*Has2*,*Invs*,*Robo2*, and *Vegfc*, were differentially expressed between E11.5 and E14.5 (\>1.2‐fold change and *P*\<0.05; adjusted for multiple testing), and among these, expression of 55 genes was upregulated whereas expression of 126 genes was downregulated ([Figure 5](#fig05){ref-type="fig"}A, [Table 2](#tbl02){ref-type="table"}).

###### 

List of Genes With Differential Expression and Methylation

  Gene Name       ACGT Chr Location   Region     \% DM     Fold Change   Function
  --------------- ------------------- ---------- --------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AI661453        Chr17 47582589      Genebody   74%\*\*   −2.02         Cellular component
  Acaca           Chr11 84088161      Genebody   73%\*\*   −2.01         Long chain fatty acid biogenesis
  Abi1            Chr2 22839713       Genebody   73%\*\*   −2.03         Negative regulation of cell growth and transformation, Ras signaling, Cardiovascular and placental development
  Aff2            ChrX 66755393       Genebody   70%\*     −2.02         RNA‐binding protein
  Atf6            Chr1 172773438      Genebody   79%\*     −2.00         Unfolded protein response during ER stress
  Arhgef12        Chr9 42820787       Genebody   74%\*     −2.02         Acts as a guanine nucleotide exchange factor
  Ank             Chr15 27482616      Genebody   59%\*\*   −2.03         Osteoblast/osteoclast differentiation, hypoxia responsive/regulated by Hif1α
  Ank             Chr15 27513341      Genebody   78%\*\*   −2.03         
  Ank             Chr15 27427229      Genebody   21%\*     −2.03         
  Ank             Chr15 27430132      Genebody   52%       −2.03         
  Atrnl1          Chr19 58000444      Genebody   84%\*\*   −4.06         G‐protein coupled receptor signaling, may regulate energy homeostasis
  Atrnl1          Chr19 57683177      Promoter   29%       −4.06         
  Atrnl1          Chr19 58054451      Genebody   35%       −4.06         
  Atxn1           Chr13 45770455      Genebody   67%\*\*   −2.02         Chromatin binding factor that represses Notch signaling.
  Brdt            Chr5 107807029      Genebody   75%\*\*   −2.00         Chromocenter organization, Spermatogenesis
  Cacna2d3        Chr14 30485237      Genebody   74%\*\*   −2.03         Voltage‐gated calcium channel activity, Regulated by promoter methylation, contractility of ventricular myocytes
  Cacna2d3        Chr14 30303225      Genebody   22%       −2.03         
  Cd180           Chr13 103491174     Genebody   66%\*     −2.00         Innate immune response, life/death decision of B‐cells
  Cdk14           Chr5 4822015        Genebody   76%\*\*   −4.07         Cell cycle regulation
  Cdk14           Chr5 5428041        Enhancer   23%       −4.07         
  Casz1           Chr4 148329448      Enhancer   80%\*\*   −2.00         Blood vessel development and lumen morphogenesis, differentially methylated in a tissue specific manner
  Cdh4            Chr2 179440423      Genebody   75%\*\*   −2.01         Calcium dependent cell adhesion, may play a role in retinal development, Regulated by methylation
  Cdh4            Chr2 179292446      Genebody   22%       −2.01         
  Cdh4            Chr2 179316146      Genebody   21%       −2.01         
  Cdh4            Chr2 179385054      Genebody   19%\*     −2.01         
  Clasp1          Chr1 120296717      Genebody   75%       −2.03         Regulation of microtubule dynamics, mitosis
  Chrna9          Chr5 66367625       Genebody   71%\*\*   −1.94         Ion transport, cochlea hair development
  Chrna9          Chr5 66348791       Enhancer   20%\*\*   −1.94         
  Col9a1          Chr1 24203890       Genebody   63%\*\*   −2.02         Expressed in developing heart, differentially methylated in cancer
  Clasp2          Chr9 113641090      Enhancer   69%\*\*   −2.02         Microtubule stabilization, mitosis
  Creb1           Chr1 64569233       Enhancer   81%\*\*   −2.02         Gene transcription, HIF‐1‐alpha transcription factor network
  D6Wsu116e       Chr6 116164345      Genebody   76%\*\*   −4.05         N/A
  Csde1           Chr3 102840451      Genebody   59%\*\*   −2.00         RNA binding and transcriptionally coupled mRNA turnover
  Disc1           Chr8 127751886      Genebody   78%\*\*   −2.02         Multiple roles in embryonic and adult neurogenesis. Associated with schizophrenia
  Dach2           ChrX 110423200      Genebody   65%\*\*   −2.04         Eye and limb development and sex determination
  Dgkb            Chr12 38744479      Genebody   73%\*\*   −1.88         Brain development
  Dnajc11         Chr4 151311759      Genebody   78%\*\*   −2.03         Heat shock binding protein
  Dlx5            Chr6 6859827        Enhancer   77%\*     −2.03         Transcriptional activator during bone development, Promotes cell proliferation, osteoblast differentiation. Cell type specific expression regulated by methylation
  Dnajc2          Chr5 21291210       Promoter   69%\*\*   2.00          DNA replication
  Dlg2            Chr7 99358525       Genebody   60%\*\*   −2.00         Regulation of synaptic stability, Chronic pain perception
  Eif2ak4         Chr2 118271831      Genebody   86%\*     −2.01         Hypoxia response
  Emilin2         Chr17 71603514      Genebody   78%\*\*   −4.05         Extracellular matrix component, regulates methylation in breast cancer
  Emilin2         Chr17 71606328      Genebody   74%\*\*   −4.05         
  Fam73a          Chr3 151956508      Genebody   81%\*\*   −2.01         Integral to membrane
  Fam111a         Chr19 12661528      Genebody   78%\*\*   −2.02         Simian virus 40 (SV40) host range restriction factor
  Fbxw7           Chr3 84630582       Genebody   77\*\*    −2.00         Mediates ubiquitination and subsequent proteasomal degradation of target proteins including NOTCH1, inactivated by promoter hypermethylation
  Fancl           Chr11 26311200      Genebody   73%\*     −2.04         Mediates monoubiquitination, may play a role in primordial germ cell proliferation
  Fancl           Chr11 26368061      Genebody   96%\*     −2.04         
  Fbxw8           Chr5 118558780      Genebody   92%\*     −2.02         Mediates ubiquitination and subsequent proteasomal degradation of target proteins, placental development
  Ftsjd2          Chr17 29820177      Genebody   67%\*\*   −2.01         Methyltransferase that mediates mRNA cap1
  Fscn1           Chr5 143721993      Promoter   67%\*     −2.03         Cell migration, motility, adhesion and cellular interactions
  Has2            Chr15 56549727      Enhancer   65%\*     −16.31        Heart valve development
  Grik4           Chr9 42754379       Promoter   79%\*     −2.04         Glutamate receptor in CNS
  Invs            Chr4 48429137       Genebody   67%\*\*   −4.05         Embryonic heart tube left development and right pattern formation
  Invs            Chr4 48288832       Promoter   24%\*     −4.05         
  Il6st           Chr13 113256622     Genebody   77%\*     −2.01         Signal transduction. Plays a role in embryonic development, vascular endothelial growth
  Hipk2           Chr6 38796532       Genebody   61%\*     −2.00         Angiogenesis, marked for degradation by hif1‐a in cancer
  Itgb1           Chr8 131241575      Genebody   78%\*\*   −2.03         Promotes endothelial cell motility and angiogenesis, Hif1 regulated in wound healing
  Itsn1           Chr16 91786820      Genebody   79%\*     −2.02         Adaptor protein linking endocytic membrane traffic and actin assembly machinery
  Isg20           Chr7 86061520       Genebody   62%\*\*   3.97          Viral response
  Itga1           Chr13 115765151     Genebody   66%\*\*   −2.04         Integrin and Collagen Binding, rapid methylation leading to initiation of megakaryocyte differentiation
  Itga1           Chr13 115800600     Genebody   20%\*\*   −2.04         
  Kcne4           Chr1 78770239       Enhancer   77%\*\*   7.87          Potassium voltage channel, cardiac function (cardiomyopathy)
  Kif26b          Chr1 180479937      Genebody   81%\*\*   −2.00         Embryonic kidney development, plays a role in compact adhesion between mesenchymal cells
  Klhl2           Chr8 67366115       Genebody   76%\*     −2.02         Mediate ubiquitination of target proteins, Plays a role in the reorganization of actin cytoskeleton
  Ksr1            Chr11 79001767      Enhancer   82%\*\*   −2.04         Promotes MEK and RAF phosphorylation and activity
  Ksr1            Chr11 78904857      Genebody   20%       −2.04         
  Limk1           Chr5 135156130      Genebody   80%\*     −2.04         Regulation of actin filament dynamics, cell motility, cell cycle progression and differentiation
  Lmf1            Chr17 25771254      Genebody   82%\*\*   −2.04         Maturation and transport of lipoprotein lipase through the secretory pathway
  Mkrn2           Chr6 115567892      Genebody   62%\*     2.01          Neurogenesis
  Ncoa7           Chr10 30373619      Genebody   75%\*\*   2.02          Co‐activation of several nuclear receptors
  Ncam1           Chr9 49570879       Genebody   61%\*     4.06          Neural adhesion, pathological angiogenesis in oxygen induced retinopathy, ventricular wall thickening in hypertension, cardiac protection
  Odz3            Chr8 49397492       Genebody   73%\*\*   −2.00         Signal transduction, neuronal growth and tumorigenesis
  Odz3            Chr8 49336206       Genebody   47%\*\*   −2.00         
  Odz3            Chr8 49341811       Genebody   21%       −2.00         
  Pam             Chr1 99716878       Enhancer   79%\*\*   4.07          Heart development and hypoxia response
  Pde5a           Chr3 122538715      Genebody   79\*\*    2.02          Signal transduction, cardiac muscle contraction and hypertrophy, hypoxia response
  Pde11a          Chr2 75840713       Genebody   70%\*     1.98          Signal transduction, may play a role in vascular smooth muscle proliferation and contraction, cardiac contractility and immune cell activation
  Pcgf5           Chr19 36450106      Promoter   71%\*     2.02          Maintenance of transcriptional repressive state in development, including that of Hox genes
  Pfkfb3          Chr2 11406131       Genebody   78%\*\*   2.03          Induced by Hif1α
  Pet112 l        Chr3 85403998       Genebody   70%\*     2.03          Glutamyl‐tRNA amidotransferase complex, Functions in mitochondria
  Pip5k1b         Chr19 24602322      Genebody   72%\*\*   4.06          Phosphorylation
  Pnkd            Chr1 74336698       Genebody   65%\*\*   2.00          Hydrolase activity, Plays an aggregative role in the development of cardiac hypertrophy via NF‐kappa‐B signaling
  Pou2f1          Chr1 167866210      Promoter   70%\*\*   −2.01         Regulates gene expression in response to stress and metabolic signals
  Ppm1 h          Chr10 122245574     Genebody   67%       4.05          Phosphatase activity, drug response in cancer, associated with systemic lupus erythematosus
  Ppm1 h          Chr10 122144175     Genebody   19%\*\*   4.05          
  Prdm16          Chr4 153999781      Genebody   68%\*\*   2.02          Transcriptional regulation, Functions as a repressor of TGF‐beta signaling
  Ppwd1           Chr13 104995653     Genebody   67%\*\*   2.02          Putative peptidylprolyl isomerase, may be involved in pre‐mRNA splicing
  Ptn             Chr6 36663240       Enhancer   75%\*\*   4.07          Angiogenesis, tumorigenesis, regulation of hematopoietic stem cell self renewal, mammary gland development
  Prmt8           Chr6 127665685      Genebody   79%\*     −2.07         Arginine methyltransferase, embryonic and neural development, regulated by auto‐methylation
  Prkca           Chr11 108120704     Genebody   86%\*\*   2.00          Regulation of transcription, cell growth, immune response, negative regulation of cell proliferation, apoptosis, differentiation, cardiac hypertrophy and angiogenesis
  Ranbp3          Chr17 56833581      Genebody   78%\*     2.02          Nuclear export, negative regulator of TGF‐beta signaling through SMAD
  Ptpro           Chr6 137362114      Genebody   71%\*\*   2.00          Wnt‐protein binding, Candidate tumor suppressor, aberrantly methylated in cancer
  Ptpru           Chr4 131336827      Genebody   69%\*\*   1.84          Cell proliferation and migration, maintenance of epithelial integrity, neural development and possible megakaryocytopoiesis
  Rbfox3          Chr11 118610022     Genebody   65%\*     1.97          RNA‐binding, associated with neurocytoma and cerebral artery occlusion
  Rhd             Chr4 134418089      Promoter   81%\*\*   −8.00         Encodes member of Rh blood group proteins
  Rbm39           Chr2 155977061      Genebody   75%       4.05          Transcriptional co‐activator for steroid nuclear receptors, involved in pre‐mRNA splicing
  Rpia            Chr6 70726365       Genebody   67%\*\*   2.02          Carbohydrate metabolism
  Robo2           Chr16 74182881      Genebody   72%       −2.00         Heart Morphogenesis, linear hear tube formation, neuronal development
  Rpn2            Chr2 157147564      Genebody   55%\*\*   2.04          Ribosome binding, Dolichyl‐diphosphooligosaccharide‐protein glycotransferase activity
  Rsu1            Chr2 13110936       Genebody   79%\*\*   2.01          Ras signal transduction pathway
  Rsu1            Chr2 13153759       Genebody   50%\*     2.01          
  Rufy2           Chr10 62447503      Genebody   65%       2.03          Alzheimer\'s disease
  Sav1            Chr12 71078443      Genebody   76%\*\*   2.03          Transcription, cell proliferation, cell death, cell migration, cell cycle exit, protein degradation and RNA splicing
  Slc24a2         Chr4 86672633       Genebody   58%\*\*   2.03          Calcium and potassium transport
  Slmap           Chr14 27308224      Genebody   79%       4.07          Myoblast fusion
  Slco5a1         Chr1 12939917       Genebody   61%       −1.97         Transporter activity
  Sorbs2          Chr8 46655637       Genebody   79%\*\*   2.02          Cytoskeletal adaptor activity and structural constituent of cytoskeleton
  Sorbs2          Chr8 46649975       Genebody   20%       2.02          
  Stxbp6          Chr12 46076554      Genebody   79%\*\*   1.96          Regulates SNARE complex formation
  St8sia5         Chr18 77402859      Enhancer   80%\*\*   2.02          Synthesis of gangliosides
  Srsf9           Chr5 115781199      Genebody   73%       2.03          Splicing
  Tex9            Chr9 72307706       Genebody   67%\*\*   2.02          ---
  Tbc1d16         Chr11 119004863     Genebody   64%\*\*   1.99          Rab GTPase activator activity
  Tbc1d16         Chr11 119017735     Genebody   76%\*\*   1.99          
  Taf4a           Chr2 179700219      Genebody   72%\*\*   2.01          Basal transcription
  Tet2            Chr3 133187569      Genebody   85%\*\*   2.01          DNA demethylation regulating transcription
  Tmem38a         Chr8 75105110       Genebody   69%\*\*   4.06          Potassium channel activity
  Tnrc6a          Chr7 130306203      Genebody   73%\*\*   2.02          Gene silencing by RNA and microRNA
  Tmem135         Chr7 96306156       Genebody   82%\*     2.02          Peroxisome organization
  Tmem135         Chr7 96397839       Genebody   29%       2.02          
  Tubg2           Chr11 101015396     Promoter   19%       −2.01         Major constituent of microtubules, structural molecule activity
  Vmn1r73         Chr7 12307910       Enhancer   63%\*\*   2.00          ---
  Wnk1            Chr6 119946851      Genebody   86%\*\*   −1.98         Heart development, regulations of cell signaling, survival and proliferations, electrolyte homeostasis, cytoskeletal reorganization and sodium and chloride ion transport
  Zbtb20          Chr16 43500263      Genebody   89%\*\*   −2.01         Transcription factor involved in hematopoiesis, oncogenesis and immune response
  Zbtb20          Chr16 43219787      Enhancer   95%       −2.01         
  Zbtb20          Chr16 43343231      Genebody   98%       −2.01         
  Zbtb20          Chr16 43455368      Genebody   97%       −2.01         
  Wnt6            Chr1 74821915       Genebody   65%       −4.35         Tissue development
  Zdhhc8          Chr16 18231749      Genebody   72%       4.00          Susceptibility to schizophrenia
  Zfp385b         Chr2 77445243       Genebody   73%\*     −2.02         Metal ion, nucleic acid, p53, and zinc ion binding, Apoptotic processes
  Zfp385b         Chr2 77629407       Genebody   21%\*     −2.02         
  Enah            Chr1 183952945      Promoter   25%       −2.01         
  Pkd2            Chr5 104885245      Promoter   22%       1.99          Tubular morphogenesis, associated with autosomal dominant polycystic kidney disease
  Mylk2           Chr2 152734667      Promoter   20%       −1.91         Cardiac function and global muscle contraction
  Ppp1r1c         Chr2 79544612       Promoter   25%       −1.93         Promotes cell cycle progression and increases cell susceptibility to TNF‐induced apoptosis
  Spns2           Chr11 72304383      Promoter   59%\*\*   −4.03         Migration of myocardial precursors; cardiovascular, immunological and neural development
  Elf1            Chr14 79879478      Promoter   31%       −4.05         Endothelial transcription factor
  Ppp1r3c         Chr19 36813263      Promoter   44%       −2.01         Glycogen synthase, Regulated by Hif1α
  Gucy1a3         Chr3 81943306       Genebody   23%\*\*   −2.02         Cardiac function, vascular smooth muscle function
  Gucy1a3         Chr3 81993497       Enhancer   23%\*\*   −2.02         
  Ank2            Chr3 126729907      Enhancer   97%       −2.01         Expression and targeting of SPTBN1 in neonatal cardiomyocytes and regulation of neonatal cardiomyocyte contraction rate
  Sfrp2           Chr3 83534574       Enhancer   30%       8.05          Cell growth and differentiation, Wnt signaling, myogenesis and eye retinal development, methylation of gene is a potential marker for colorectal cancer
  Erbb4           Chr1 68142043       Genebody   23%       −4.04         Heart development, cardiac muscle differentiation and postnatal cardiomyocyte differentiation, CNS development, neural crest cell migration, gene transcription, cell proliferation, differentiation, migration and apoptosis
  Erbb4           Chr1 68846422       Genebody   20%       −4.04         
  Erbb4           Chr1 68938673       Genebody   38%       −4.04         
  Erbb4           Chr1 68954441       Genebody   20%       −4.04         
  Erbb4           Chr1 69128731       Genebody   24%       −4.04         
  Mysm1           Chr4 94660067       Enhancer   28%\*\*   −2.00         Histone modification and transcriptional co‐activation
  Foxp1           Chr6 98892345       Genebody   19%       −2.04         Cardiomyocyte proliferation
  Foxp1           Chr6 99008217       Genebody   22%\*     −2.04         
  Foxp1           Chr6 99018432       Genebody   34%       −2.04         
  Foxp1           Chr6 99163145       Genebody   20%       −2.04         
  Foxp1           Chr6 99197140       Genebody   23%       −2.04         
  Foxp1           Chr6 99357158       Genebody   22%       −2.04         
  Foxp1           Chr6 99391693       Enhancer   43%\*     −2.04         
  Unc5c           Chr3 141321392      Genebody   19%       −8.07         Cell migration in neural development, axon extension and induction of apoptosis
  Unc5c           Chr3 141342275      Genebody   26%       −8.07         
  Unc5c           Chr3 141359065      Genebody   20%       −8.07         
  Sox5            Chr6 143990289      Genebody   20%       −4.01         Embryonic development, cell fate determination, transcriptional regulation
  Sox5            Chr6 144141969      Genebody   19%       −4.01         
  Psd3            Chr8 70278799       Genebody   19%\*     −2.03         Guanine nucleotide exchange factor for ARF6
  Psd3            Chr8 70338543       Genebody   96%       −2.03         
  Psd3            Chr8 70459139       Genebody   23%\*     −2.03         
  Dock1           Chr7 142059905      Genebody   28%       −2.01         Cytoskeletal rearrangements necessary for phagocytosis of apoptotic cells and in cell motility Guanine nucleotide exchange factor
  Dock1           Chr7 142061686      Genebody   19%       −2.01         
  Dock1           Chr7 142073658      Genebody   30%       −2.01         
  Dock1           Chr7 142115224      Genebody   24%       −2.01         
  Dock1           Chr7 142136783      Genebody   24%       −2.01         
  Dock1           Chr7 142190260      Genebody   53%       −2.01         
  Wwox            Chr8 117142250      Genebody   31%       −2.03         Apoptosis, TGFB1 signaling and TGFB1‐mediated cell death. Inhibits Wnt signaling
  Wwox            Chr8 117354691      Genebody   26%       −2.03         
  Wwox            Chr8 117632214      Genebody   22%       −2.03         
  Vegfc           Chr8 55148115       Enhancer   21%       2.02          Angiogenesis and endothelial cell growth
  Vegfc           Chr8 55239360       Genebody   18.5%\*   2.02          
  Vegfc           Chr8 55247617       Genebody   22%       2.02          
  Pard3           Chr8 129591554      Genebody   28%\*     −2.00         Adaptor protein, asymmetrical cell division and cell polarization, plays a role in epithelial tight junctions
  Pard3           Chr8 129640346      Genebody   96%\*\*   −2.00         
  Pard3           Chr8 129830952      Genebody   96%       −2.00         
  Pard3           Chr8 129845627      Genebody   21%\*\*   −2.00         
  Pard3           Chr8 129875488      Genebody   22%       −2.00         
  Pard3           Chr8 129914177      Genebody   24%       −2.00         
  Thsd4           Chr9 59846658       Genebody   19%\*     −2.00         Attenuates TGFB signaling
  Thsd4           Chr9 59968525       Genebody   22%       −2.00         
  Thsd4           Chr9 60041974       Genebody   19%\*     −2.00         
  Thsd4           Chr9 60098887       Genebody   96%\*     −2.00         
  Rora            Chr9 68624882       Genebody   19%\*\*   −2.01         Regulated genes involved in lipid metabolism
  Rora            Chr9 68726640       Genebody   24%\*\*   −2.01         
  Rora            Chr9 68865723       Genebody   19%       −2.01         
  Utrn            Chr10 12126998      Genebody   20%\*     2.02          Anchors cytoskeleton to plasma membrane
  Utrn            Chr10 12213501      Genebody   20%       2.02          
  Utrn            Chr1012395503       Genebody   19%       2.02          
  Mef2c           Chr13 83687636      Genebody   96%       −1.99         Transcription activator controls cardiac morphogenesis and myogenesis, plays a role in vascular development
  Mef2c           Chr13 83755977      Genebody   30%\*\*   −1.99         
  Mef2c           Chr13 83797333      Genebody   25%       −1.99         
  Odz2            Chr11 35940645      Genebody   35%\*     −1.98         Neural development
  Odz2            Chr11 36164904      Genebody   20%\*     −1.98         
  Odz2            Chr11 36400641      Genebody   32%\*\*   −1.98         
  Odz2            Chr11 36725324      Genebody   27%\*\*   −1.98         
  Ptprk           Chr10 27825617      Genebody   20%\*     −2.01         Regulation of cell contact and adhesions, tumor invasion/metastasis, Negative regulator of EGFR signaling
  Ptprk           Chr10 28084547      Genebody   24%       −2.01         
  Ptprk           Chr10 28226602      Genebody   24%\*\*   −2.01         
  Enox1           Chr14 77538059      Enhancer   97%       −2.00         Oxidoreductase activity, nucleotide binding
  Enox1           Chr14 77771534      Genebody   23%       −2.00         
  Enox1           Chr14 77876556      Genebody   20%\*     −2.00         
  Enox1           Chr14 77977395      Genebody   20%\*\*   −2.00         
  Zfpm2           Chr15 40787554      Genebody   29%       −2.01         Transcription regulator important in heart morphogenesis and coronary vessel development from epicardium
  Zfpm2           Chr15 40824705      Genebody   95%\*\*   −2.01         
  Zfpm2           Chr15 40848971      Genebody   19%       −2.01         
  Dach1           Chr14 98263585      Genebody   97%\*     −1.99         Transcription factor important in organogenesis
  Dach1           Chr14 98304412      Genebody   26%       −1.99         
  Dach1           Chr14 98510700      Genebody   96%       −1.99         
  Erc2            Chr14 28475844      Genebody   97%       −1.99         Cytomatrix organization at nerve terminal active zones regulating release of neurotransmitters
  Erc2            Chr14 28668685      Genebody   30%       −1.99         
  Erc2            Chr14 28822634      Genebody   95%       −1.99         
  Erc2            Chr14 28845440      Genebody   24%       −1.99         
  Vps13b          Chr15 35600466      Genebody   23%\*\*   −1.99         Protein sorting in post Golgi membrane traffic, may play a role in development and function of the eye, hematological system and the CNS
  Vps13b          Chr15 35777972      Genebody   19%       −1.99         
  Vps13b          Chr15 35817931      Genebody   23%\*     −1.99         
  2810403A07Rik   Chr3 88506464       Genebody   84%       −2.01         RNA binding
  Tle4            Chr19 14528880      Genebody   20%\*     −2.01         Transcriptional co‐repressor of members in Wnt signaling
  Tle4            Chr19 14621827      Genebody   24%       −2.01         
  Prkg1           Chr19 30823222      Genebody   19%\*     −2.02         Regulates cardiac function, smooth muscle contraction, platelet activation and adhesion
  Prkg1           Chr19 31528132      Genebody   24%       −2.02         
  Prkg1           Chr19 31595749      Genebody   20%       −2.02         
  Hif1a           Chr12 75032797      Genebody   25%       −2.00         Hypoxia response, Master transcriptional regulator
  Malt1           Chr18 65586771      Promoter   19%\*     −2.00         NF‐kappaB activation
  Igf2r           Chr17 12965268      Promoter   44%       −2.02         Activation of TGF‐β. Intracellular trafficking of lysosomal enzymes and degradation of IGF2, tumorigenesis, Paternally imprinted
  Krtap9‐1        Chr11 99731190      Promoter   27%       8.00          Hair shaft formation
  Ccdc40          Chr11 119085948     Promoter   20%       −4.03         Motile cilia function. Ciliary dyskinesia type 15
  Cftr            Chr6 18119186       Promoter   20%       −2.00         Chloride channel and enzyme binding, associated with cystic fibrosis
  Cftr            Chr6 18242079       Genebody   42%       −2.00         
  Pdzd2           Chr15 12315935      Genebody   23%       2.02          Prostate tumorigenesis
  Pdzd2           Chr15 12342544      Genebody   27%       2.02          
  Pdzd2           Chr15 12521967      Promoter   19%       2.02          
  Elovl2          Chr13 41317598      Promoter   23%       −4.04         Atherosclerosis, protein binding and fatty acid elongase activity
  Gpr18           Chr14 122316980     Promoter   96%       1.98          Regulation of immune system, bipolar disorder
  Rpn1            Chr6 88030514       Promoter   24%       −2.01         Dolichyl‐diphosphooligosaccharide‐protein glycotransferase activity
  Mosc1           Chr1 186637543      Promoter   19%       −4.12         ---
  Tmem150c        Chr5 100589921      Promoter   25%       −2.04         ---
  Shroom3         Chr5 93236380       Promoter   27%       −2.01         Regulation of cell shape in neuroepithelium
  Calb1           Chr4 15806105       Promoter   24%       −1.95         Functions in purkinje cells
  Gpr61           Chr3 107962781      Promoter   22%\*\*   8.01          G‐protein coupled receptor signaling
  Cd40            Chr2 164871483      Enhancer   96%       −2.02         Immune and inflammatory response
  Ephx1           Chr1 182951005      Promoter   23%       2.02          Cis‐stilbene‐oxide hydrolase activity, epoxide hydrolase activity. Plays a role in preeclampsia
  Arhgap29        Chr3 121628392      Enhancer   96%       −2.00         Rho GTPase activator activity, essential role in blood vessel tubulogenesis
  Fbxl4           Chr4 22244260       Enhancer   21%       −2.02         Cell cycle control
  Fbxl4           Chr4 22264607       Enhancer   21%       −2.02         
  Zmat3           Chr3 32233835       Genebody   96%\*\*   −1.96         TP53‐dependent growth regulatory pathway and TP53‐mediate apoptosis, inhibits tumor cell growth
  Zmat3           Chr3 32278426       Enhancer   22%       −1.96         
  Fam125b         Chr2 33790838       Enhancer   23%\*\*   −2.03         Vesicular trafficking
  Serpinb2        Chr1 109370955      Enhancer   31%       −4.08         Serine‐type endopeptidase inhibitor activity
  Rims1           Chr1 22615396       Genebody   97%\*     −2.02         Exocytosis, maintenance of neurotransmitter release and regulation of release during short‐term synaptic plasticity
  Rims1           Chr1 22763512       Genebody   96%       −2.02         
  Dst             Chr1 34249899       Genebody   20%       −2.01         Cytoskeletal linker protein, Regulation of keratinocyte polarity and mobility
  Dst             Chr1 34315083       Genebody   20%       −2.01         
  Dst             Chr1 34322642       Genebody   26%       −2.01         
  Etl4            Chr2 20373784       Genebody   23%       2.00          Intervertebral disk development
  Etl4            Chr2 20576360       Genebody   95%\*     2.00          
  Esrrg           Chr1 189527991      Genebody   46%       −2.00         Transcriptional activator via estrogen response elements
  Esrrg           Chr1 189976300      Genebody   21%\*     −2.00         
  Dnm3            Chr1 163949959      Genebody   22%       −1.99         Megakaryocyte development, likely involved in endocytosis
  Dnm3            Chr1 164108264      Genebody   40%\*\*   −1.99         
  Rbms1           Chr2 60615270       Genebody   25%       −2.02         Cell cycle progression, apoptosis, DNA replication and gene transcription.
  Rbms1           Chr2 60789032       Genebody   19%       −2.02         
  Lrba            Chr3 86163560       Genebody   23%       −2.01         Signal transduction and vesicle trafficking
  Lrba            Chr3 86267521       Genebody   21%       −2.01         
  Plcb1           Chr2 134819839      Genebody   23%       −1.99         Intracellular transduction of extracellular signals
  Plcb1           Chr2 135145732      Genebody   25%       −1.99         
  Meis2           Chr2 115688950      Genebody   96%       −2.01         Transcriptional regulation
  Meis2           Chr2 115750462      Genebody   96%       −2.01         
  Bach2           Chr4 32560314       Genebody   21%\*     −2.00         Transcriptional regulation
  Bach2           Chr4 32629036       Genebody   21%       −2.00         
  Kcnd3           Chr3 105447527      Genebody   16%\*     −1.84         Smooth muscle contraction, heart rate, insulin secretion, neuronal excitability and cell volume
  Fam19a1         Chr6 96068370       Genebody   31%       −1.91         Regulators of immune cells and cells of the nervous system
  Fam19a1         Chr6 96235296       Genebody   19%\*\*   −1.91         
  Drosha          Chr15 12715566      Enhancer   22%       −2.03         Cleaves ds‐RNA in micro RNA processing
  Drosha          Chr15 12817558      Genebody   27%       −2.03         
  Gsk3b           Chr16 38062422      Enhancer   20%       −2.01         Negative regulator in hormonal control of glucose homeostasis, Wnt signaling and the regulation of transcription factors and microtubules. Regulates NFatc1 expression. Mediates development of insulin resistance
  Gsk3b           Chr16 38138300      Genebody   20%\*\*   −2.01         
  Gsk3b           Chr16 38218276      Genebody   96%       −2.01         
  Pmm2            Chr16 8627532       Enhancer   33%       −2.02         Glycoprotein biosynthesis
  Osta            Chr16 32515415      Enhancer   31%       −2.00         Transporter activity
  Krt8            Chr15 101867475     Enhancer   23%       −4.02         Signal transduction and cellular differentiation
  Slc38a4         Chr15 96905406      Enhancer   96%       −2.00         Sodium‐dependent amino acid transporter
  Slc38a2         Chr15 96516885      Enhancer   20%\*     −2.03         Supply of maternal nutrients to fetus through placenta, transport of amino acids at blood‐brain barrier
  Adra2a          Chr19 54118496      Promoter   26%       1.99          Mediates the catecholamine‐induced inhibition of adenylate cyclase

Table provides differentially expressed genes with corresponding differential methylation (DM) sites. Bolded DM values indicate decreased methylation at E14.5 whilst unbolded DM values indicates increased methylation at E14.5.

\*Notes *P*\<0.05 in methylation changes and \*\*notes *P*\<0.01 in methylation changes. Gene functions are summarized.

![Expression changes for selected genes with differentially methylated sites. A, Gene expression analysis (n=3) of 350 differentially methylated genes between E11.5 and E14.5 showing that 181 genes are differentially expressed and 79 of those genes show consistent changes in DNA methylation. B, The top 15 upregulated genes (red) and downregulated genes (green) in E14.5. The solid and open triangles mark differentially methylated sites in regulatory regions (promoter proximal or distal) and gene bodies, respectively. The up and down directions of triangles indicate increased and decreased methylation, respectively.](jah3-3-e000976-g5){#fig05}

Recent studies of the correlation between DNA methylation and gene expression have found that increased promoter and enhancer methylation often lead to gene silencing while DNA methylation at gene bodies corresponds with gene activation.^[@b53]^ We therefore examined the functional correlation between differential gene expression and changes in DNA methylation. We found that among the top 15 downregulated genes at E14.5, 4 of them contained an increase in methylation of sites located within promoter or enhancer regions and an additional 4 showed decreased methylation in their gene bodies ([Figure 5](#fig05){ref-type="fig"}B). Of the top 15 upregulated genes, 4 had decreased methylation in their enhancers and 3 exhibited increased methylation in their gene bodies. We found that, while 12.7% (23) of the 181 differentially expressed genes contained differentially methylated sites within the promoter region, methylation of only 60.8% (14) of those genes was predictive of their expression difference between E11.5 and E14.5, and overall 43.6% (79) of genes had differentially methylated sites predictive of expression change. The findings suggest that not all DNA methylation is functional; most genes are regulated independent of methylation.^[@b54]^ Nevertheless, the observed correlations between gene expression and DNA methylation during heart development do support that DNA methylation regulates expression of a subset of genes during heart development.

Increased DNA Methylation at Enhancers is Associated With Decreased Expression of the Cardiac‐Essential Gene *Has2* in the Developing Heart
-------------------------------------------------------------------------------------------------------------------------------------------

These correlations suggest a regulatory relationship between DNA methylation and cardiac‐important genes. Notably, *Has2* is essential for endocardial to mesenchymal transformation and heart valve formation.^[@b51],[@b55]--[@b56],[@b6]^ Gene network analysis using the Genemania open freeware (<http://www.genemania.org>) further revealed potential genetic and/or physical interactions among genes or pathways involved in heart development. The top 20 genes that were identified to interact (either genetically or physically) with Has2 by the network analysis were significantly enriched with functions involved in heart development. These genes included *Cdh2*,*Epo*,*Kcna5*,*Myocd*,*Tbx20*,*Hand1*,*Mef2c*, and *Nfatc4* ([Figure 6](#fig06){ref-type="fig"}).^[@b49],[@b57]--[@b59]^ Regulation of these genes by DNA methylation to influence their expression will ultimately affect their pathway and downstream functions, which are essential for heart development.

![Network analysis for DNA methylation‐regulated Has2. Top: Genemania analysis reveals multiple relationships between Has2 and multiple cardiac genes including Myocd, Kcna5, Mef2c, Hand1, Tbx20 and Nfatc4. Bottom: Top functions of genes in the Has2 network.](jah3-3-e000976-g6){#fig06}

Previous knockout studies in mice have shown that *Has2* is essential for development of cardiac valves and septa.^[@b51],[@b56]^ Here, our DNA methylation analysis indicated that an ACGT site located within 1 kb of a previously determined enhancer of *Has2*, marked by enriched H3K27ac at E14.5,^[@b44]^ exhibited an increase in methylation as confirmed by Sequenom\'s MassArray ([Figure 7](#fig07){ref-type="fig"}A). Based on what is known about DNA methylation, we expected to see a decrease in *Has2* expression at E14.5, with confirmation by qPCR analysis ([Figure 7](#fig07){ref-type="fig"}B). To further characterize its expression in the developing hearts, we carried out RNA in situ hybridization. The results showed that *Has2* expression was predominately expressed in the endocardial cells and their mesenchymal progeny cells that form the primitive heart valves at E11.5, but its expression markedly diminished by E14.5 ([Figure 7](#fig07){ref-type="fig"}C), consistent with its function in endocardial to mesenchymal transformation around E11.5 for heart valve development.

![*Has2* expression is regulated by Dnmt3b. A, MassArray showing increased *Has2* enhancer methylation at E14.5 (n=2). B, RT‐qPCR showing decreased *Has2* expression at E14.5 (n=3). C, RNA in situ hybridization showing that *Has2* expression is predominantly in the atrioventricular canal (avc), with less expression in the myocardium (myo) at E11.5; and the expression is diminished by E14.5. mv/tv, mitral/tricuspid valve; ivs, interventricular septum. D, IHC showing Dnmt3b is predominantly expressed in AVC at E11.5. E, X‐gal staining showing the Nfatc1‐Cre mediated LacZ expression in the AVC at E11.5. F, RT‐qPCR showing that deletion of *Dnmt3b* resulted in increased *Has2* expression at E11.5 and E14.5 (n=3). Error bars represent standard error. \*Marks statistical significance (*P*\<0.001, 2 factor ANOVA in \[F\]). ANOVA indicates analysis of variance; CKO, conditional knockout; IHC, immunohistochemistry; RT‐qPCR, quantitative real‐time polymerase chain reaction; WT, wild type.](jah3-3-e000976-g7){#fig07}

Dnmt3b Suppresses Expression of the Cardiac‐Essential Gene *Has2* in the Developing Heart
-----------------------------------------------------------------------------------------

We next chose to determine experimentally the function of DNA methylation in *Has2* expression in the developing heart valves. To overcome the difficulty of not being able to directly assay the in vivo role of methylation of the *Has2* enhancer on the expression of the gene in the developing heart, we inactivated the activity of DNA methyltransferase 3b (*Dnmt3b*), which is responsible for de novo methylation during embryonic development.^[@b22]^ First, we showed that, like *Has2*,*Dnmt3b* was expressed predominately in the endocardial cells, precursor cells for the heart valves ([Figure 7](#fig07){ref-type="fig"}D). The expression pattern of *Dnmt3b* suggests that it has a role in DNA methylation in the endocardial cell lineages and may therefore regulate *Has2* expression in the developing heart valves. Indeed, deletion of *Dnmt3b* in the endocardial cells and their valve progeny, using the endocardial‐specific *Nfatc1*^*Cre*^ mice ([Figure 7](#fig07){ref-type="fig"}E),^[@b9]^ resulted in significantly increased *Has2* expression in the developing heart valves at E11.5 and E14.5 ([Figure 7](#fig07){ref-type="fig"}F). The results support that DNA methylation of the *Has2* enhancer plays a role in repressing its expression during heart development.

Discussion
==========

In this study, we generated a developmental profile of DNA methylation using methyl sensitive tiny fragment enrichment coupled with massively parallel sequencing (MSFE/MPS). Greater coverage and increased sensitivity for the detection of methylation are achieved using this method compared with microarray‐based techniques. The method also provides more detailed information specific for ACGT sites and is capable of detecting intermediate levels of methylation, allowing for detection of modest changes in methylation.^[@b60]^

Our technique was adapted from the HpaII tiny fragment enrichment by ligation mediated PCR (HELP)‐tagging assay developed by Suzuki et al^[@b32]--[@b33]^ In the original HELP‐tagging assay a methylation sensitive restriction enzyme, HpaII, is used to assess methylation of CpG dinucleotides located within its recognition site 5′‐CCGG‐3′. We modified this technique by using a different methylation‐sensitive restriction enzyme, HpyCH4IV, whose recognition site is 5′‐ACGT‐3′ even though it lacks a methylation‐insensitive isoschizomer. Previous studies have confirmed that sequencing reads/tags from a single methylation sensitive restriction enzyme without its isoschizomer are highly correlated with methylation status.^[@b32],[@b61]^ Furthermore, we used independent validation methods, such as LUMA and MassArray to confirm methylation levels determined by the MSFE/MPS.

HpyCH4IV provides comparable genome coverage to HpaII, having 1.7 million recognition sites located throughout the genome. Future studies using both enzymes will not only double the coverage but also examine and compare DNA methylation in both CG rich and non‐CG rich regions. In addition, the use of HpyCH4IV will, in future studies, allow us to directly examine, in a genome‐wide manner, the effect of methylation on transcription factor binding sites such as Hif1α, whose consensus binding sequence is 5′‐ACGTG‐3′ and has been shown to be regulated by DNA methylation.^[@b62]^

The original analytical pipeline was also modified to analyze our MPS data generated by using HpyCH4IV.^[@b37]^ Within the HELP‐tagging protocol an internal experimental control is used in which contaminating fragments are recognized based on the absence of the digested restriction site.^[@b60]^ Additionally, to better identify differentially methylated sites between developmental stages, we generated a threshold to determine levels of methylation at individual loci. We employed these modifications to generate a genome wide developmental profile of methylation at ACGT sites in the developing heart. The results showed no significant global change in methylation over mid‐stage heart development, although our study did not include the repetitive regions of the genome as they could not be aligned and thus discarded in the pipeline. We further confirmed that there is no significant change in global methylation patterns using LUMA.

Although drastic changes in global DNA methylation are not present during heart development, differential methylation was detected at a small subset of individual loci throughout the genome in this study. Furthermore, we detected a number of differentially methylated sites in which the change in methylation between E11.5 and E14.5 corresponds with the observed change in expression of the nearby gene, suggesting that there is a regulatory relationship between DNA methylation and the expression of cardiac‐important genes including *Has2*.

*Has2* has previously been identified to be essential for heart development, playing a role in epicardial cell differentiation, heart valve development, and septation.^[@b51],[@b55]^ A DNA methylation‐regulated cardiac gene program was generated by performing a network analysis for Has2 using Genemania. Network analysis revealed multiple relationships between Has2 and other cardiac‐important gene products, including previously mentioned Tbx20, involved in endocardial cushion formation and heart valve remodeling,^[@b57]^ Hand 1 involved in ventricle morphogenesis,^[@b58]^ and Nfatc4, a member of the nuclear factor of activated T‐cell family that are known to be essential for heart development.^[@b59]^ Additional connections have been identified between Has2 and Gjc1 (Connexin45), known to play an important role in cardiac morphogenesis and conduction,^[@b63]^ and Cdh2, Epo, Kcna5, Mef2c, and Myocd, which are essential for heart development and function.

We further studied methylation of *Has2* and its expression in the developing heart in detail, as it has an increase in enhancer methylation that corresponds with a decrease in its expression over mid‐stage heart development in the developing heart valves. We showed by qPCR analysis, RNA in situ hybridization, and genetic knockout that Dnmt3b regulates *Has2* expression, possibly through its enhancer methylation.

In this study we were able to assay 1.64 million ACGT sites for potential changes in DNA methylation during mid‐stage cardiac development, identifying 2901 differentially methylated sites, and determined a number of developmentally important cardiac genes that are likely to be regulated by DNA methylation. However, current methods for studying functionality of DNA methylation at specific sites in the developing heart are limited. We circumvented this limitation by revealing the dependence of *Has2* expression on *Dnmt3b* expression in the developing heart valves. Our results are mainly discovery and by necessity preliminary, and will require a much larger sample size to detect more sites with more subtle DNA methylation changes between the 2 developmental stages.

In conclusion, our results support an essential role for DNA methylation in the regulation of cardiac essential genes during heart development and suggest abnormal DNA methylation may contribute to the pathogenesis of congenital heart disease. Using this study as a starting point, we plan to investigate further candidate genes as well as the role of additional epigenetic modifications that may play a role in heart development and disease.
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